Back to top
more

Mesoblast Limited (MESO)

(Delayed Data from NSDQ)

$16.64 USD

16.64
177,673

-0.36 (-2.12%)

Updated Aug 24, 2026 04:00 PM ET

After-Market: $16.64 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Down 35.1% in 4 Weeks, Here's Why You Should You Buy the Dip in Mesoblast Limited (MESO)

by Zacks Equity Research

The heavy selling pressure might have exhausted for Mesoblast Limited (MESO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Zacks Equity Research

Mesoblast Limited (MESO) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

by Zacks Equity Research

After losing some value lately, a hammer chart pattern has been formed for Mesoblast Limited (MESO), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Zacks Equity Research

Wall Street Analysts Believe Mesoblast Limited (MESO) Could Rally 157%: Here's is How to Trade

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 156.9% in Mesoblast Limited (MESO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Equity Research

Strength Seen in Mesoblast Limited (MESO): Can Its 6.1% Jump Turn into More Strength?

by Zacks Equity Research

Mesoblast Limited (MESO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

Company News for Jan 12, 2021

by Zacks Equity Research

Companies in the news are: MESO, ODP, LLY, AZZ

Zacks Equity Research

Is the Options Market Predicting a Spike in Mesoblast (MESO) Stock?

by Zacks Equity Research

Investors need to pay close attention to Mesoblast (MESO) stock based on the movements in the options market lately.

Zacks Equity Research

Novartis' (NVS) COVID-19 Study Fails to Meet Primary Endpoint

by Zacks Equity Research

Novartis' (NVS) late-stage study on ruxolitinib in COVID-19 patients did not meet its primary endpoint.

Zacks Equity Research

Implied Volatility Surging for Mesoblast (MESO) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Mesoblast (MESO) stock based on the movements in the options market lately.

Zacks Equity Research

Novartis (NVS) Partners With Mesoblast for ARDS Cell Therapy

by Zacks Equity Research

Novartis (NVS) enters into a license agreement with Mesoblast for remestemcel-L for the treatment of acute respiratory distress syndrome and other indications.

Zacks Equity Research

Are Options Traders Betting on a Big Move in Mesoblast (MESO) Stock?

by Zacks Equity Research

Investors need to pay close attention to Mesoblast (MESO) stock based on the movements in the options market lately.